- Home
- LTRN vs ANTX Comparison
LTRN vs ANTX Comparison
Compare LTRN & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRN
- ANTX
- Stock Information
- Founded
- LTRN 2013
- ANTX 2017
- Country
- LTRN United States
- ANTX United States
- Employees
- LTRN N/A
- ANTX N/A
- Industry
- LTRN Biotechnology: Pharmaceutical Preparations
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- LTRN Health Care
- ANTX Health Care
- Exchange
- LTRN Nasdaq
- ANTX Nasdaq
- Market Cap
- LTRN 36.2M
- ANTX 31.9M
- IPO Year
- LTRN 2020
- ANTX 2022
- Fundamental
- Price
- LTRN $2.99
- ANTX $1.28
- Analyst Decision
- LTRN Hold
- ANTX Hold
- Analyst Count
- LTRN 1
- ANTX 5
- Target Price
- LTRN N/A
- ANTX $3.50
- AVG Volume (30 Days)
- LTRN 50.0K
- ANTX 918.3K
- Earning Date
- LTRN 11-07-2024
- ANTX 11-13-2024
- Dividend Yield
- LTRN N/A
- ANTX N/A
- EPS Growth
- LTRN N/A
- ANTX N/A
- EPS
- LTRN N/A
- ANTX N/A
- Revenue
- LTRN N/A
- ANTX N/A
- Revenue This Year
- LTRN N/A
- ANTX N/A
- Revenue Next Year
- LTRN N/A
- ANTX N/A
- P/E Ratio
- LTRN N/A
- ANTX N/A
- Revenue Growth
- LTRN N/A
- ANTX N/A
- 52 Week Low
- LTRN $2.79
- ANTX $0.87
- 52 Week High
- LTRN $11.99
- ANTX $22.22
- Technical
- Relative Strength Index (RSI)
- LTRN 36.73
- ANTX 65.23
- Support Level
- LTRN $3.04
- ANTX $0.98
- Resistance Level
- LTRN $3.57
- ANTX $1.04
- Average True Range (ATR)
- LTRN 0.25
- ANTX 0.07
- MACD
- LTRN -0.05
- ANTX 0.02
- Stochastic Oscillator
- LTRN 14.81
- ANTX 52.58
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.